Idioma:

Early decline in serum phospho-CSE1L levels in vemurafenib/sunitinib-treated melanoma and sorafenib/lapatinib-treated colorectal tumor xenografts

Lee, Woan-Ruoh ; Shen, Shing-Chuan ; Shih, Yi-Hsien ; Chou, Chia-Lun ; Tseng, Jonathan Te-Peng ; Chin, Szu-Ying ; Liu, Kao-Hui ; Chen, Yen-Chou ; Jiang, Ming-Chung

Journal of translational medicine, 2015-06, Vol.13 (1), p.191-191, Article 191 [Periódico revisado por pares]

England: BioMed Central Ltd

Texto completo disponível

Citações Citado por

Enviar para

Título:
Early decline in serum phospho-CSE1L levels in vemurafenib/sunitinib-treated melanoma and sorafenib/lapatinib-treated colorectal tumor xenografts
Autor: Lee, Woan-Ruoh ; Shen, Shing-Chuan ; Shih, Yi-Hsien ; Chou, Chia-Lun ; Tseng, Jonathan Te-Peng ; Chin, Szu-Ying ; Liu, Kao-Hui ; Chen, Yen-Chou ; Jiang, Ming-Chung
Assuntos: Analysis ; Animals ; Antibodies ; Antibodies, Neoplasm - immunology ; Cancer ; Care and treatment ; Cell Line, Tumor ; Cell Proliferation - drug effects ; Cellular Apoptosis Susceptibility Protein - blood ; Colon cancer ; Colorectal Neoplasms - blood ; Colorectal Neoplasms - drug therapy ; Colorectal Neoplasms - pathology ; Drug resistance ; Drug therapy ; Extracellular Signal-Regulated MAP Kinases - metabolism ; Gastrointestinal diseases ; Health aspects ; Humans ; Indoles - pharmacology ; Indoles - therapeutic use ; Male ; Melanoma ; Melanoma - blood ; Melanoma - drug therapy ; Melanoma - pathology ; Mice, Inbred NOD ; Mice, SCID ; Mortality ; Niacinamide - analogs & derivatives ; Niacinamide - pharmacology ; Niacinamide - therapeutic use ; Phenylurea Compounds - pharmacology ; Phenylurea Compounds - therapeutic use ; Phosphorylation - drug effects ; Pyrroles - pharmacology ; Pyrroles - therapeutic use ; Quinazolines - pharmacology ; Quinazolines - therapeutic use ; Sulfonamides - pharmacology ; Sulfonamides - therapeutic use ; Tumors ; Viral antibodies ; Xenograft Model Antitumor Assays
É parte de: Journal of translational medicine, 2015-06, Vol.13 (1), p.191-191, Article 191
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Descrição: Although targeted therapies have improved the clinical outcomes of cancer treatment, tumors resistance to targeted drug are often detected too late and cause mortality. CSE1L is secreted from tumor and its phosphorylation is regulated by ERK1/2. ERK1/2 is located downstream of various growth factor receptors and kinases, the targets of most targeted drugs. Serum phospho-CSE1L may be a marker for monitoring the efficacy of targeted therapy. We used mice tumor xenograft model to study the assay of serum phosphorylated CSE1L for early detecting the efficacy of targeted drugs. The phosphorylation status of CSE1L in vemurafenib and sorafenib treated tumor cells were assayed by immunoblotting with antibody against phosphorylated CSE1L. Ras activation increased phospho-CSE1L expression in B16F10 melanoma cells. Vemurafenib and sorafenib treatment did not significantly reduce the total CSE1L levels; however, they inhibited ERK1/2 and CSE1L phosphorylation in A375 melanoma cells and HT-29 colorectal cancer cells. In the melanoma xenograft model, serum phospho-CSE1L level declined 5 days after vemurafenib/sunitinib treatment and 3 days after sorafenib/lapatinib treatment in the HT-29 colon cancer xenograft model. Vemurafenib/sunitinib and sorafenib/lapatinib treatments resulted in tumor regression. Our results indicated that serum phospho-CSE1L is useful for early detecting the efficacy of targeted therapy in initial treatment and for monitoring emerging secondary drug resistance to facilitate timely therapeutic decision making.
Editor: England: BioMed Central Ltd
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Anterior Resultado 9 Avançar Ir para próxima página

Realização: Logos de Redes Sociais:

Early decline in serum phospho-CSE1L levels in vemurafenib/sunitinib-treated melanoma and sorafenib/lapatinib-treated colorectal tumor xenografts

Lee, Woan-Ruoh ; Shen, Shing-Chuan ; Shih, Yi-Hsien ; Chou, Chia-Lun ; Tseng, Jonathan Te-Peng ; Chin, Szu-Ying ; Liu, Kao-Hui ; Chen, Yen-Chou ; Jiang, Ming-Chung

England: BioMed Central Ltd

Buscando em bases de dados remotas. Favor aguardar.